Phase 3 Agitation Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled241 locationsNCT06937229
Recruiting
Phase 2Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled14 locationsNCT07284472
Recruiting
Phase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer DiseaseAgitation
Sunnybrook Health Sciences Centre112 enrolled6 locationsNCT04516057
Recruiting
Phase 3
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
AgitationAlzheimer's Type Dementia
Suven Life Sciences Limited375 enrolled44 locationsNCT05397639
Recruiting
Phase 2Phase 3
Acute Agitation in Emergency Psychiatry
Agitation
Lone Baandrup132 enrolled1 locationNCT06752616
Completed
Phase 3
Pain relief as a treatment for agitation and aggression in persons with dementia.
Behavioural and Psychological Symptoms of DementiaAgitation and AgressionPain+2 more
National Health and Medical Research Council90 enrolled1 locationACTRN12611000062921